The effects of add-on acarbose on the levels of chronic inflammatory state and gut microbiota in patients with type 2 diabetes mellitus

The effects of add-on acarbose on the levels of chronic inflammatory state and gut microbiota in patients with type 2 diabetes mellitus: a four-week, single center, randomized, parallel, open label clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001753

Enrollment

Unknown

Registered

2011-11-30

Start date

2008-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Interventions

Treatment group:Acarbose+conventional hypoglycemic therapy

Control:conventional hypoglycemic therapy

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Males or females >= 18 years; 2. Hospitalized patients with type 2 diabetes who had been not treated with acarbose before enrollment.

Exclusion criteria

Exclusion criteria: 1. Already on acarbose before hospitalization; 2. Gastrointestinal disorders; 3. LADA and other autoimmunity disease; 4. Acute infections; 5. Moderate to severe liver, kidney dysfunction, ie ALT/AST > 2.5 times upper limit of the normal range or Ccr<25ml/min; 6. Previously allergic reaction to any of the ingredients; 7. Any condition where increased gas in the intestine may make it worse,such as Roemheld syndrome, large hernia, intestinal obstruction and intestinal ulcer.

Design outcomes

Primary

Measure	Time frame
fasting capillary glucose;	—

Countries

China

Contacts

Public ContactBenli Su

benlisu_dalian@163.com+86 15541178798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026